What Is a Synthetic Persona? The Definition for Pharma

A synthetic persona is a model generated stand in for a customer, built from existing research and public data, used to produce simulated answers to questions you would otherwise put to a real person.

That is the whole thing. Everything else is implementation detail, and most of the confusion in this market comes from vendors describing the detail instead of the definition.

This page sets out what they are, how they are built, and what they are worth in each of your three pharma audiences. It also covers where they fail, and the test any of them should pass before touching a commercial decision.

What is a synthetic persona, precisely?

Three things have to be true, or what you are being sold is something else.

It stands in for a specific customer type rather than a general audience. It generates responses rather than retrieving them. Its outputs are then treated as if they were research, which is the part that creates all the risk.

The related terms are used loosely, so here is the vocabulary as it is actually used.

A synthetic respondent is one simulated individual answering a question. A synthetic panel or synthetic audience is many of them queried together to produce something resembling survey results. An AI persona usually means the same thing with the emphasis on characterization rather than sampling. A digital twin is a different idea borrowed from engineering and applied loosely here, normally meaning a simulated individual built from that specific person's own data rather than from a segment. In the research literature the practice of using a language model to stand in for survey respondents is sometimes called silicon sampling.

What none of them are is a measurement. A synthetic persona produces an estimate of what a category of person might say. That is a hypothesis, and treating it as a finding is the single most common error you will encounter in this field.

How are they actually built?

Three layers, and the quality of the whole thing is set by the first.

Source material. Your prior survey research, claims or behavioral data, public literature, transcripts, and whatever the vendor has in its own library. This defines what the persona can know.

The model. A large language model that generates plausible responses in character. This defines how the persona talks.

Calibration. Adjusting outputs so they resemble known distributions, usually by benchmarking against the client's historic data or syndicated category research. This defines how confident everybody feels, which is not the same as how accurate it is.

Notice the dependency. A synthetic persona cannot know anything your source material does not contain. It can only recombine, extrapolate and phrase. When a vendor says a persona is grounded in your research, read that as inheriting your research, including everything your research got wrong.

Are they equally useful across your three audiences?

Not remotely, and this is the distinction nobody selling them makes.

Your market has three customers. A physician chooses, a payer covers, a patient uses. Simulation fidelity differs so much across the three that treating them as one capability is the first mistake.

Physicians, medium fidelity and checkable. There is abundant public material in a clinician's professional register, from literature to guidelines to conference commentary. A model can produce a credible HCP voice. More importantly you can check it, because you have real prescribing behavior to score the simulation against. This is the audience where synthetic work is most defensible.

Patients, low fidelity and unverifiable. This is where the pitch is strongest and the ground is weakest. You usually cannot speak to patients, so there is no real voice available to validate the simulated one. The audience you most want to simulate is the one you can least check, and a confident simulation you cannot falsify is not evidence. It is a well written assumption.

The behavior you would want it to predict is also severe. A 2026 JAMA study summarized by Johns Hopkins found insurer rejections reached 40.7% of initial brand name attempts in 2024. Of those rejected scripts, 48.4% were never followed by a fill of that drug or anything in its class within 90 days. No simulated patient told anyone that was coming.

Payers, lowest fidelity of the three. Formulary decisions run on contracts, rebate economics, net price and committee politics. Almost none of that is in the text a model learned from, and the parts that matter most are confidential by design. A simulated payer will produce an articulate account of clinical value and miss the actual decision rule entirely.

So the honest ranking is physician first, patient a distant second with disclosure, payer last and mostly not worth doing.

Worth remembering why the temptation is strong. Veeva Pulse data reported by BioSpace put HCP accessibility at 45%, down from 60% eighteen months earlier. As real access closes, simulated access gets easier to sell.

What are they legitimately good for?

Four jobs, all of them upstream of real research rather than instead of it.

Replacing an assumption. At the design stage you are not choosing between a synthetic persona and real data. You are choosing between a persona and one brand manager's opinion, formed in a meeting, unchallenged. Simulation beats opinion. That is a genuine gain and the strongest case for the whole category.

Generating hypotheses to test. Run a hundred simulated reactions, find the three objections you had not anticipated, then go and check those three with real people. You have used the simulation to aim the expensive instrument.

Pressure testing a design before you build it. Walk a simulated patient through your access workflow and you will find the step where the instructions make no sense. That is a usability review, and it is a reasonable thing to automate.

Reaching what you cannot reach in time. A rare disease population, a market where recruitment takes four months, a decision due in three weeks. Simulation here is a considered compromise rather than a shortcut, provided you label it as one.

Where do they fail?

Four failure modes, and the first is structural rather than fixable.

They model the rationale, not the decision. A language model learns how people explain choices, not how people make them. Your physician decides on context, habit, trust and the difficult patient she saw on Tuesday, then produces a tidy reason when asked. The model reproduces the reason. What you receive is a fluent account of why someone would do something they will not actually do.

That gap matters more in your market than in most, because predisposition rather than stated preference is what moves prescribing. Simulated reasoning is a good model of the part of the customer that does not decide.

The calibration trap. Ground a persona in your own survey history and you have encoded your existing blind spots at speed. If your sentiment data was not predicting commercial outcome before, a model trained on it will reproduce that failure faster and with more confidence.

Homogenization. Models regress toward the center of their training distribution. Your outliers, your frustrated minority, your early signal, all the people who actually tell you something new, are precisely the voices a simulation smooths away.

Confident error. A real respondent hesitates, contradicts herself and says she does not know. A simulated one answers everything, immediately, in complete sentences. Fluency reads as reliability to a human audience and the two are unrelated.

Effort research outside pharma shows how much is hiding in the friction a tidy answer skips over. Gartner found 62% of customer service channel transitions are high effort, in industries where the company can watch it happen. A simulated customer never reports being worn down, because being worn down is not a thing you articulate, it is a thing you quit over.

How should you validate one?

Three tests, and anything that cannot pass them does not belong in a decision.

Provenance. Can the signal be traced to something a human did, rather than something a model inferred about what a human might say? Know which you are holding.

Predisposition or rationale. Does it capture what moved the person, or the story told afterwards? A synthetic respondent can only produce the latter, which caps what it can ever be worth.

Predictive hold. Run the simulation against a cohort whose outcome you already know, blind. Compare its prediction to realized script to start conversion, time to therapy and persistence. Publish the error rate. Repeat quarterly, because model behavior drifts.

That third test is the one the industry is skipping. A fidelity score a vendor defines, computes and reports on its own work is a marketing number. An error rate against your own outcomes is evidence. Insist on the second before you buy.

What rules should govern its use?

Four, and they are not onerous.

Never let a synthetic output become a reported number. Use it to decide what to measure, never as the measure.

Label it everywhere it appears. Any chart built on simulated respondents carries that fact in the title, not in a footnote, so that a decision made on it is made knowingly.

Validate before adoption and on a schedule after it. One accuracy check at purchase tells you about a model that no longer exists. Models are updated, retrained and replaced underneath you, and nobody sends a memo.

Keep real listening funded. The strongest argument for simulation is that it is cheaper than research, which is also how a company talks itself out of the research it needs.

Deloitte's 2025 research found that only 28% of HCPs believe pharma's engagement strategies meet their needs, against 82% of life sciences executives who say they are satisfied. You will not simulate your way across a 54 point perception gap.

The routes that produce real signal are set out in voice of the customer in pharma. The cheapest real signal you already own is covered in voice of the frontline.

So should you use them?

Yes, for the four jobs above, with the three tests applied and the four rules in place.

The position is simple. Simulation beats assumption and loses to evidence. Deploy it where the alternative is a guess. Keep it away from anything you report. Hold it to the same standard as any other instrument claiming to tell you about your customer.

That standard is the point. The measures it should ultimately be scored against are in how to measure customer experience in pharma, and the discipline that connects what you hear to what you realize is Customer Excellence.

Key takeaways

A synthetic persona is a model generated stand in for a customer, producing simulated answers from existing research and public data.
Fidelity differs enormously by audience. Physicians are checkable, patients are unverifiable, payers run on economics a text model never saw.
They model the rationale rather than the decision, which caps their value in a market driven by predisposition.
Grounding a persona in your own survey history encodes your existing blind spots and reproduces them faster.
A vendor defined fidelity score is marketing. An error rate against your own realized outcomes is evidence.

Questions to ask before you buy one

Which of my three audiences is this for, and what is your accuracy evidence for that audience specifically?
What source material grounds it, and what happens to the output if that material was biased?
Show me a blind holdout test against real outcomes, with the error rate published.
How often is it revalidated, and who pays for that?
What decisions would you tell me not to make on this?

About the author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse. Related reading: Voice of the customer in pharma, three ways to hear, Voice of the frontline and What is value leakage in pharma?

< Older Post

Newer Post >

[PRACTICE NOTE] Your Call Plan Isn’t the Problem. Your Customer Context Is.

March 15, 2026

Why healthcare professionals now judge pharmaceutical engagement against the best experiences in their lives, and what that means for the future of commercial leadership. When commercial performance falters, the reflex inside many pharmaceutical organizations is to adjust the machinery of field execution. Leaders revisit call plans, recalibrate targeting models, and increase the volume of activity in the hope that more precision or more frequency will restore momentum. For decades this system has been treated as the central instrument of commercial performance, determining which physicians are prioritized, how frequently representatives engage, and how resources are deployed across territories. Yet the growing gap between commercial effort and commercial impact suggests a deeper issue. T he problem is rarely the design of the call plan itself. It is the context in which healthcare professionals now operate. Physicians are navigating increasingly complex clinical, administrative, and informational environments, and that evolving reality now shapes prescribing behavior far more than the cadence of promotional interactions. What many organizations are experiencing is a widening Customer Context Gap. Commercial systems were designed for a time when prescribing decisions could be influenced primarily through promotional interaction and product information. Today physicians operate inside a far more complex reality shaped by administrative burden, reimbursement constraints, digital information overload, and growing expectations for seamless support across the entire care journey. In this environment the physician’s decision is influenced not only by clinical evidence but also by how easily a therapy fits into the practical realities of care delivery. When commercial models remain anchored in promotional activity while the customer’s context has fundamentally changed, even the most disciplined call plan struggles to deliver the outcomes it was designed to produce. Closing this gap requires a different way of thinking about commercial performance. The question is no longer how to optimize promotional activity but how to align the organization around the real journeys through which physicians help patients receive therapy. Prescribing decisions unfold within complex sequences of clinical evaluation, reimbursement navigation, patient readiness, and ongoing support. When commercial strategy is designed around these journeys rather than isolated interactions, the role of the field force begins to evolve. Representatives are no longer positioned primarily as messengers of information but as partners in removing barriers that slow care. Organizations that recognize this shift begin redesigning their commercial systems accordingly, aligning field engagement, digital support, access programs, and patient services around the same goal: helping healthcare professionals help patients move from clinical intent to successful treatment. From Promotional Activity to Customer Journeys The pharmaceutical industry has historically organized commercial activity around the moment of promotion. Call plans, targeting models, and message sequencing were designed to influence prescribing behavior primarily through informational engagement with healthcare professionals. While this model brought structure and scale to commercial operations, it reflects an earlier era in which the path from clinical awareness to prescribing action was comparatively linear. Today the journey is far more complex. Physicians must navigate an intricate landscape of clinical evidence, treatment guidelines, payer requirements, prior authorization processes, patient affordability concerns, and adherence challenges. Prescribing a therapy is no longer a single decision point. It is the beginning of a chain of events that determines whether a patient ultimately receives and remains on treatment. This is why the commercial conversation must expand beyond the traditional moment of prescription to encompass three interconnected journeys. The first is the Path-to-Prescribe , where scientific evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. The second is the Path-to-Fulfill, where access, affordability, patient readiness, and operational support determine whether that recommendation ultimately becomes therapy in the patient’s hands. The third is the Path-to-Adhere , where ongoing patient support, monitoring, and engagement determine whether patients remain on therapy long enough to realize the intended clinical benefit. Science drives the Path to Prescribe, where evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. Experience shapes the Path to Fulfill, where access, affordability, and patient readiness determine whether that recommendation becomes therapy in the patient’s hands. Sustained outcomes depend on the Path to Adhere, where ongoing support, monitoring, and engagement ensure patients remain on therapy long enough to realize its intended clinical benefit. When commercial organizations focus almost exclusively on the first while leaving the latter journeys fragmented and burdened, a significant portion of therapeutic value is lost between intention and impact. In many therapeutic areas, the result appears in the persistent gap between prescriptions written, prescriptions filled, and therapies sustained—gaps that reflect not a failure of science but a failure of system design. Recognizing these three journeys shifts the unit of focus from promotional activity to the real-world pathways through which care is delivered. It reframes the role of the field force, the purpose of digital engagement, and the design of patient support programs around a single objective: reducing the friction that stands between clinical intent, treatment initiation, and sustained patient outcomes. Customer Context Is the New Commercial Variable For much of the pharmaceutical industry’s history, commercial performance was largely explained by a familiar set of variables. Product efficacy, clinical differentiation, promotional reach, and sales force execution determined the trajectory of most brands. When performance lagged, leaders adjusted those levers by refining segmentation, optimizing targeting, and recalibrating call plans. Today those traditional levers still matter, but they no longer explain commercial outcomes on their own. A far more powerful variable has entered the equation: customer context. HCPs now operate within an environment defined not only by clinical complexity and administrative burden but also by rising expectations shaped by their experiences outside healthcare. Physicians are also consumers. In their personal lives they interact daily with companies such as Apple, Amazon, Tesla, and Netflix that anticipate their needs, remove friction, and simplify complex processes through thoughtful design. These experiences quietly reset the benchmark for competence, responsiveness, and respect for their time. When those same physicians step into their clinical roles, they do not shed those expectations. They carry them with them. The contrast between the seamless orchestration of their consumer experiences and the fragmented systems surrounding many healthcare interactions becomes difficult to ignore. What once felt acceptable now feels unnecessarily burdensome. This dynamic represents the Consumer-Grade Imperative. Healthcare professionals increasingly evaluate pharmaceutical engagement not against other pharmaceutical companies but against the best experiences they encounter anywhere in their lives. In this environment even a clinically superior therapy can struggle if the surrounding system makes it difficult to initiate treatment, navigate reimbursement, or support patient adherence. Customer context therefore becomes the new commercial variable. It determines whether scientific differentiation translates into practical adoption. It shapes whether prescribing intent becomes therapy initiation and whether therapy initiation becomes sustained patient outcomes. Call plans were designed to manage activity. Customer context requires organizations to manage journeys. The Field Force in the Era of Customer Context Recognizing customer context as the defining commercial variable inevitably reshapes how the role of the field force is understood. For decades the pharmaceutical sales representative has been positioned primarily as the carrier of scientific information. Call plans optimized the frequency and sequencing of these interactions to ensure that physicians received consistent messaging. That role does not disappear, but the environment surrounding it has changed profoundly. Physicians today are navigating administrative burden, payer complexity, digital information overload, and increasing time pressure. In this environment they are not simply seeking more information. They are seeking clarity, simplicity, and support that helps them navigate the complexity surrounding treatment decisions. This shift transforms the representative from a messenger of information into something far more valuable: a partner in removing friction from the care journey. Conversations move beyond repeating clinical claims toward understanding the practical barriers that physicians and their teams face as they attempt to initiate and sustain therapy for patients. The most effective field forces are therefore supported by commercial systems designed around journeys rather than activities. Representatives are equipped not only with scientific messaging but with the insight and coordination required to address obstacles across prescribing, reimbursement, and patient support. Field engagement becomes a catalyst for problem solving rather than simply a vehicle for promotion. From Call Plans to Customer-Aligned Commercial Systems If customer context has become the defining commercial variable, then the systems designed to support the field must evolve accordingly. The traditional call plan was built to manage activity. It provided structure for how frequently physicians were engaged, how territories were covered, and how resources were deployed. Yet activity alone does not determine whether therapies ultimately reach patients. What determines impact is whether the commercial system surrounding the physician reduces or increases the burden of delivering care. A customer-aligned commercial system begins with the journeys through which physicians help patients move from diagnosis to treatment and beyond. Marketing clarifies the scientific story. Sales provides trusted relationships and real-time understanding of physician needs. Access teams simplify reimbursement pathways. Patient support programs reduce administrative burden. Digital engagement reinforces and extends human interaction. The result is a commercial system that operates less like disconnected functions and more like an integrated network designed to help physicians help patients. This is the essence of Customer Excellence. It aligns the entire commercial enterprise around the real-world context in which care is delivered. The problem was never the call plan. The problem was the context. Key Takeaways Commercial performance in pharma organizations has traditionally been managed through field execution mechanics, yet the effectiveness of those mechanics increasingly depends on how well they reflect the real-world context in which physicians operate. Customer context has become the most pivotal commercial variable as administrative burden, payer complexity, and consumer-grade expectations reshape how prescribing decisions are made. HCPs now evaluate pharmaceutical engagement against the best experiences they encounter anywhere in their lives, raising the standard for clarity, responsiveness, and ease. Optimizing promotional activity alone is no longer sufficient. Commercial success depends on reducing friction across the journeys physicians navigate as they move patients from diagnosis to treatment. Customer Excellence represents the structural response, aligning marketing, sales, access, digital engagement, and patient support around the real journeys of care delivery . Diagnostic Questions to Consider Are we optimizing the activity of our field force, or designing commercial systems that support the real journeys physicians navigate to help patients receive therapy? How well do we understand the administrative, reimbursement, and operational barriers physicians encounter after they decide to prescribe a therapy? Do our commercial systems reduce the burden placed on physicians and their staff , or unintentionally add to the complexity of care delivery? Are we benchmarking our engagement against other pharma companies , or against the best experiences physicians encounter in their lives as consumers? Have our investments in digital platforms simplified the physician’s experience, or multiplied the number of disconnected interactions they must manage? Are we still managing performance through activity metrics alone , or beginning to understand the context that ultimately determines whether therapies reach patients? Closing Reflection The pharma and life sciences industry has spent decades refining the mechanics of field execution. Call plans, segmentation models, and targeting systems brought structure and discipline to commercial organizations. Yet the environment surrounding physicians has evolved far more rapidly than the systems built to support them. Healthcare professionals now operate in a world defined by consumer-grade expectations for clarity, responsiveness, and ease. When the experience of engaging with a pharmaceutical company fails to reflect those expectations, the contrast becomes impossible to ignore. Organizations that recognize this shift will redesign their commercial systems around the realities of modern care delivery. They will move beyond managing activity and toward understanding the context in which physicians help patients receive treatment. In doing so they will close the gap between scientific innovation and real-world impact. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a hands-on commercial excellence architect and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

Tan building with a hanging sign against a clear blue sky